Overview
Acute myeloid leukemia (AML) with CBFB::MYH11 rearrangement is usually considered a favorable-risk subtype, meaning patients often respond well to initial chemotherapy. However, long-term outcomes are not uniformly excellent. Even in this group, relapse remains a major concern, with about 40% of patients eventually experiencing disease return. This study examined whether the level of measurable residual disease (MRD) based on CBFB::MYH11 transcript levels after early chemotherapy could better identify which patients need allogeneic hematopoietic cell transplantation (allo-HCT) in first complete remission (CR1).
The central question was practical and important: after induction chemotherapy, how can clinicians decide whether a patient with otherwise favorable-risk AML should continue with chemotherapy consolidation or move to transplant? The study suggests that MRD assessment after the second chemotherapy cycle may provide a more reliable guide than earlier or later measurements.
Why CBFB::MYH11 matters
CBFB::MYH11 is a fusion gene created by a chromosomal rearrangement commonly seen in core-binding factor AML. This genetic subtype often has better initial treatment response than many other forms of AML, but “favorable risk” does not mean “low risk” in every patient. Some patients have hidden residual leukemia that is not visible under the microscope but can be detected by molecular testing.
That hidden disease is known as measurable residual disease, or MRD. In CBFB::MYH11-rearranged AML, MRD can be tracked using transcript levels of the fusion gene. A higher transcript level after treatment suggests that leukemia cells remain in the body and may later cause relapse. This makes MRD a powerful tool for post-remission decision-making.
Study design and patient population
The investigators analyzed 186 patients with CBFB::MYH11-rearranged AML who received intensive induction chemotherapy. The study evaluated transcript levels after the first, second, and third chemotherapy cycles and compared how well each time point predicted disease-free survival (DFS) and overall survival (OS).
Disease-free survival refers to the length of time after treatment during which a patient remains free of relapse or death from any cause. Overall survival measures the time from treatment until death from any cause. Both outcomes are critical in AML, where the goals are not only achieving remission but also maintaining it safely over time.
The researchers also compared two post-remission strategies for patients with high MRD after cycle 2: allo-HCT in CR1 versus chemotherapy consolidation. Allo-HCT involves replacing the patient’s diseased bone marrow with healthy blood-forming stem cells from a donor. It can provide a strong anti-leukemia effect but also carries meaningful risks, including infection, graft-versus-host disease, and treatment-related mortality.
Main findings
A key result was that CBFB::MYH11 transcript levels after the second and third chemotherapy cycles were strongly correlated. In other words, patients who still had substantial molecular disease after cycle 2 tended to remain MRD-positive after cycle 3 as well. This means cycle 2 already captured much of the biologic risk information.
Among all the tested time points, the post-cycle 2 CBFB::MYH11 transcript level was the strongest predictor of both DFS and OS. It outperformed transcript assessments after cycles 1 and 3, suggesting that cycle 2 is an especially informative checkpoint for treatment planning.
The most clinically important threshold identified in this study was a post-cycle 2 CBFB::MYH11 level of at least 1.0%. Patients at or above this level had significantly worse outcomes. After adjusting for other variables, a level ≥1% after cycle 2 was independently associated with inferior DFS and OS.
Specifically, the hazard ratio for worse DFS was 3.84, and for worse OS it was 3.98. A hazard ratio above 1 indicates higher risk; in this setting, patients with persistent molecular disease were much more likely to relapse or die than those with lower transcript levels.
Who benefited from transplant?
The study then focused on the subgroup of patients whose CBFB::MYH11 level remained ≥1.0% after cycle 2. In this high-risk group, outcomes were notably better for patients who underwent allo-HCT in CR1.
At 3 years, both DFS and OS were 91.7% in the allo-HCT group. By comparison, among patients who received chemotherapy consolidation rather than transplant, 3-year DFS was 47.8% and 3-year OS was 72.9%. These differences suggest that transplant may substantially reduce the risk of relapse in patients with persistent molecular disease after early treatment.
In multivariate analysis, allo-HCT in CR1 improved 3-year DFS compared with chemotherapy consolidation, with a hazard ratio of 0.24. This indicates a strong protective effect against disease recurrence or death from disease. However, during the available follow-up period, no statistically significant overall survival advantage was confirmed. This may reflect the relatively small number of patients, the impact of salvage therapies after relapse, or the need for longer follow-up to detect survival differences.
Clinical meaning of the results
These findings have practical implications for AML treatment planning. Traditionally, patients with favorable-risk AML are often treated with chemotherapy consolidation rather than immediate transplant in first remission, because transplant can be more toxic and is not always necessary. But this study shows that molecular response after cycle 2 may identify a subset of patients whose risk is no longer truly favorable.
In simple terms, if the leukemia marker remains above 1.0% after the second cycle, the patient may be in a biologically higher-risk category despite the favorable genetic label. For these patients, moving to allo-HCT in CR1 may offer better protection against relapse than continuing chemotherapy alone.
This approach reflects a modern trend in leukemia care: treatment decisions are becoming increasingly individualized and guided by molecular response rather than genetics alone. A favorable karyotype or fusion gene is helpful, but it should not override evidence that residual leukemia persists after therapy.
How MRD guides personalized AML care
Measurable residual disease testing is changing how hematologists think about remission. A patient can be in complete remission by standard laboratory and microscopic criteria yet still harbor enough leukemia cells to relapse later. Molecular MRD testing provides a more sensitive view of disease burden.
For CBFB::MYH11 AML, the fusion transcript is an excellent MRD marker because it can be measured quantitatively. This allows clinicians to follow trends over time rather than rely only on a yes-or-no remission status. A falling level suggests treatment is working. A persistently elevated level, especially after early cycles, signals the need to consider a more aggressive post-remission approach.
The current study supports using the second chemotherapy cycle as a decision point. This timing is useful because it occurs early enough to plan donor search, transplant workup, and supportive care if needed, while still allowing enough time to gauge response to induction therapy.
Limitations to keep in mind
Although the results are compelling, several caveats are important. This was not a randomized trial, so treatment allocation to transplant or chemotherapy consolidation was not random. That means patient selection factors may have influenced the results, even though multivariate analysis helps reduce confounding.
Also, the study focused on patients treated with intensive induction chemotherapy at selected centers, so the findings may not apply equally to older patients, frail patients, or those receiving lower-intensity regimens. In addition, OS benefits can be harder to show than DFS benefits, especially when effective salvage treatments are available after relapse.
Another important point is that the 1.0% threshold is study-specific and should be interpreted within the context of the assay used, local laboratory standards, and broader clinical judgment. MRD results should never be used in isolation; they are best interpreted alongside age, fitness, donor availability, cytogenetic co-features, mutation profile, and patient preferences.
Practical takeaways for clinicians and patients
For clinicians, the message is that MRD after the second chemotherapy cycle may be the most informative early checkpoint in CBFB::MYH11-rearranged AML. Patients with transcript levels below 1.0% may continue with chemotherapy consolidation, while those at or above 1.0% should be considered for allo-HCT in CR1, assuming they are suitable transplant candidates.
For patients, the key lesson is that being classified as “favorable risk” does not guarantee low relapse risk. Molecular testing can reveal whether treatment has truly cleared the leukemia. If residual disease remains after early therapy, a transplant may offer a better chance of durable remission.
Shared decision-making remains essential. The transplant decision must balance relapse risk against the short- and long-term complications of allo-HCT. But this study provides stronger evidence that early MRD-guided risk stratification can help choose the right path for the right patient.
Conclusion
In CBFB::MYH11-rearranged AML, the MRD level after the second chemotherapy cycle appears to be the most powerful early marker for predicting outcome. A post-cycle 2 transcript level of 1.0% or higher identifies a subgroup with significantly worse prognosis. For these patients, allo-HCT in first complete remission may improve disease control and reduce relapse risk compared with chemotherapy consolidation alone.
Overall, the study supports a more personalized approach to favorable-risk AML: not all patients with this genetic subtype should be managed the same way. Early molecular response, especially after cycle 2, can help guide whether transplantation should be part of first-remission therapy.
